LH Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of 6.36% compared to Labcorp Holdings's net margin of 5.4%. Labcorp Holdings's return on equity of 9.01% beat Delcath Systems's return on equity of -40.28%.

Labcorp Holdings has a consensus price target of $279.06, signalling upside risk potential of 13.45%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 114.03%. Given that Delcath Systems has higher upside potential than Labcorp Holdings, analysts believe Delcath Systems is more attractive than Labcorp Holdings.

Labcorp Holdings has a beta of 0.819, which suggesting that the stock is 18.086% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.871, suggesting its less volatile than the S&P 500 by 12.874%.

Labcorp Holdings has a quarterly dividend of $0.72 per share corresponding to a yield of 1.17%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Labcorp Holdings pays 32.59% of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings quarterly revenues are $3.3B, which are larger than Delcath Systems quarterly revenues of $19.8M. Labcorp Holdings's net income of $212.8M is higher than Delcath Systems's net income of $1.1M. Notably, Labcorp Holdings's price-to-earnings ratio is 28.44x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings is 1.57x versus 6.91x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Quest Diagnostics has a net margin of 6.36% compared to Labcorp Holdings's net margin of 8.3%. Labcorp Holdings's return on equity of 9.01% beat Quest Diagnostics's return on equity of 13.14%.

Labcorp Holdings has a consensus price target of $279.06, signalling upside risk potential of 13.45%. On the other hand Quest Diagnostics has an analysts' consensus of $184.10 which suggests that it could grow by 10.22%. Given that Labcorp Holdings has higher upside potential than Quest Diagnostics, analysts believe Labcorp Holdings is more attractive than Quest Diagnostics.

Labcorp Holdings has a beta of 0.819, which suggesting that the stock is 18.086% less volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.805%.

Labcorp Holdings has a quarterly dividend of $0.72 per share corresponding to a yield of 1.17%. Quest Diagnostics offers a yield of 1.86% to investors and pays a quarterly dividend of $0.80 per share. Labcorp Holdings pays 32.59% of its earnings as a dividend. Quest Diagnostics pays out 38% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings quarterly revenues are $3.3B, which are larger than Quest Diagnostics quarterly revenues of $2.7B. Labcorp Holdings's net income of $212.8M is lower than Quest Diagnostics's net income of $220M. Notably, Labcorp Holdings's price-to-earnings ratio is 28.44x while Quest Diagnostics's PE ratio is 21.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings is 1.57x versus 1.87x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health has a net margin of 6.36% compared to Labcorp Holdings's net margin of -46.77%. Labcorp Holdings's return on equity of 9.01% beat Guardant Health's return on equity of -8518.58%.

Labcorp Holdings has a consensus price target of $279.06, signalling upside risk potential of 13.45%. On the other hand Guardant Health has an analysts' consensus of $59.67 which suggests that it could grow by 24.82%. Given that Guardant Health has higher upside potential than Labcorp Holdings, analysts believe Guardant Health is more attractive than Labcorp Holdings.

Labcorp Holdings has a beta of 0.819, which suggesting that the stock is 18.086% less volatile than S&P 500. In comparison Guardant Health has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.2%.

Labcorp Holdings has a quarterly dividend of $0.72 per share corresponding to a yield of 1.17%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Labcorp Holdings pays 32.59% of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings quarterly revenues are $3.3B, which are larger than Guardant Health quarterly revenues of $203.5M. Labcorp Holdings's net income of $212.8M is higher than Guardant Health's net income of -$95.2M. Notably, Labcorp Holdings's price-to-earnings ratio is 28.44x while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings is 1.57x versus 7.62x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of 6.36% compared to Labcorp Holdings's net margin of -13.34%. Labcorp Holdings's return on equity of 9.01% beat Natera's return on equity of -19.19%.

Labcorp Holdings has a consensus price target of $279.06, signalling upside risk potential of 13.45%. On the other hand Natera has an analysts' consensus of $192.78 which suggests that it could grow by 29.91%. Given that Natera has higher upside potential than Labcorp Holdings, analysts believe Natera is more attractive than Labcorp Holdings.

Labcorp Holdings has a beta of 0.819, which suggesting that the stock is 18.086% less volatile than S&P 500. In comparison Natera has a beta of 1.729, suggesting its more volatile than the S&P 500 by 72.907%.

Labcorp Holdings has a quarterly dividend of $0.72 per share corresponding to a yield of 1.17%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Labcorp Holdings pays 32.59% of its earnings as a dividend. Natera pays out -- of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings quarterly revenues are $3.3B, which are larger than Natera quarterly revenues of $501.8M. Labcorp Holdings's net income of $212.8M is higher than Natera's net income of -$66.9M. Notably, Labcorp Holdings's price-to-earnings ratio is 28.44x while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings is 1.57x versus 10.39x for Natera. Usually stocks with elevated PS ratios are considered overvalued.